4-amino-1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidin-2-one

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 英文名称: 4-amino-1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-propylpyrimidin-2-one
• 化学式: C12H18N6O3
• 分子量: 294.31
• InChiKey: CHOWDJMNKIBFDO-IVZWLZJFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER
  申请人：(INSERM) Institut National de la Santé et de la Recherche Médicale

  公开号：EP3429597A1

  公开（公告）日：2019-01-23
• US6136791A
  申请人：——

  公开号：US6136791A

  公开（公告）日：2000-10-24
• US6432924B1
  申请人：——

  公开号：US6432924B1

  公开（公告）日：2002-08-13
• [EN] CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER<br/>[FR] INHIBITEURS DE CYTIDINE DÉSAMINASE POUR LE TRAITEMENT DU CANCER DU PANCRÉAS
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017158396A1

  公开（公告）日：2017-09-21

  The present invention relates to methods and pharmaceutical compositions for use in the treatment of pancreatic cancer in a subject in need thereof.
• [EN] CYTIDINE DEAMINASE INHIBITORS FOR THE TREATMENT OF PANCREATIC CANCER<br/>[FR] INHIBITEURS DE LA CYTIDINE DÉSAMINASE POUR LE TRAITEMENT DU CANCER DU PANCRÉAS
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017158050A1

  公开（公告）日：2017-09-21

  The present invention relates to methods and pharmaceutical compositions for use in the treatment of pancreatic cancer in a subject in need thereof. The inventors showed that targeting cytidine deaminase sensitizes cancer cells to chemotherapy (gemcitabine dFdC) both in vitro and in vivo in experimental models of PDA, with very high efficacy. To their surprise, CDA targeting in the absence of chemotherapy strongly alters cell proliferation and tumor progression. In particular, the present invention relates to a method for treating pancreatic cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a cytidine deaminase inhibitor in combination with an anti-pancreatic cancer treatment selected from the group consisting of CHK1 inhibitor, WEE1 inhibitor, ART inhibitor, DHODH inhibitor or gene therapy.